Summit Therapeutics Inc — Liquidità (NASDAQ:SMMT) | MetaTrader

Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Flusso di cassa derivante dalle attività operative -48.11 M-72.59 M-41.58 M-76.76 M-142.11 M-322.93 M -322.93 M Flussi di cassa derivanti dalle attività di investimento -421 K-306 K-624 K-587.77 M-205.34 M-174.31 M -174.31 M Liquidità derivante dalle attività di finanziamento 50.55 M77.92 M620.24 M86.51 M381.23 M617.53 M 617.53 M Liquidità libera -48.53 M-72.89 M-42.21 M-76.89 M-142.25 M-323.59 M -323.59 M

Notizie

Stifel avvia copertura su Summit Therapeutics con rating buy

Cantor Fitzgerald conferma rating Overweight su Summit Therapeutics

Why Is Ironwood (IRWD) Down 13.9% Since Last Earnings Report?

Tracking Baker Brothers Portfolio – Q4 2025 Update (NASDAQ:INCY)

Jefferies declassa il rating di Summit Therapeutics per rischi legati agli studi

Jefferies downgrades Summit Therapeutics stock rating on trial risks

Micron and Facebook among market cap stock movers on Friday

Summit Therapeutics alla Citizens Life Sciences Conference: approfondimenti strategici su ivonescimab

Summit Therapeutics at The Citizens Life Sciences Conference: Strategic Insights on Ivonescimab

Summit Therapeutics Inc. (SMMT) Presents at The Citizens Life Sciences Conference 2026 Transcript

Summit Therapeutics al TD Cowen Conference: Focus strategico su Ivonesimab

Summit Therapeutics at TD Cowen Conference: Strategic Focus on Ivonesimab